Dr. Garrett is manager of the Health Education Center at Mission Hospitals in Asheville, North Carolina.
Intravenous thrombolysis with alteplase is the only approved treatment for acute ischemic stroke, but its efficacy and safety when administered > 3 hours after the onset of symptoms have not been established. A recent study of patients with ischemic stroke, confirmed by computed tomography showed a benefit of the drug when given beyond the typical 3-hour limit. Researchers studied a total of 821 patients given alteplase or placebo 3 to 4.5 hours after the onset of stroke symptoms. The major end point studied was disability at 90 days.
The median time for the administration of alteplase was 3 hours 59 minutes. More patients had a favorable outcome with alteplase (52.4%) than with placebo (45.2%). The incidence of intracranial hemorrhage was higher with alteplase. Mortality did not differ between the groups. The authors concluded that alteplase may offer significant benefit to patients beyond the time that is specified by the manufacturer; however, further study is needed.
Protein C, protein S, and antithrombin deficiencies are associated with increased risk of thromboembolism (TE). Dutch researchers recently conducted a retrospective study of 552 subjects representing 84 families to determine if a history of venous TE predisposed the subjects to arterial TE (ATE). Detailed information on previous venous TE, ATE, anticoagulant use, and atherosclerosis risk factors was collected.
Of 552 subjects, 35% had protein S, 39% had protein C, and 26% had antithrombin deficiency. Overall, annual incidences of ATE were 0.34% in deficient subjects versus 0.17% in nondeficient subjects; the hazard ratio was 2.3. After adjusting for atherosclerosis risk factors and clustering within families, deficient subjects had a 4.7-fold higher risk for ATE before 55 years of age versus 1.1 thereafter, compared with nondeficient family members. For separate deficiencies, the risks were 4.6-, 6.9-, and 1.1-fold higher in protein S?, protein C?, and antithrombindeficient subjects, respectively, before 55 years of age. History of venous TE was not related to subsequent ATE.
The researchers concluded that subjects with protein S or protein C deficiency, but not antithrombin deficiency, have a higher risk for ATE before 55 years of age that is independent of prior venous TE.
Earlier work in this area of study showed that responders to clopidogrel therapy were more often smokers. The current paper expands on that initial observation and demonstrates how an external factor, smoking, can influence platelet reactivity in patients treated with a prodrug that is metabolized by the hepatic cytochrome P450 pathway. The researchers studied 104 current smokers and 155 nonsmokers who were undergoing elective coronary stenting. They were either already on clopidogrel or received a 600-mg loading dose. Current smokers on chronic clopidogrel showed significantly greater platelet inhibition and significantly lower platelet aggregation than their nonsmoking counterparts. This also was true of smokers who received the loading dose, compared with nonsmokers who received the loading dose. Smoking was a highly significant independent predictor of low platelet aggregation.
Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.
Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?
Clinical features with downloadable PDFs